Filing Flows › BeOne Medicines (ONC) › Q2 2026 › vs Q1 2026
BeOne Medicines (ONC) Q2 2026 vs Q1 2026 (quarter over quarter)
BeOne Medicines's revenue rose $192M (+13%) from $1.5B in Q1 2026 to $1.7B in Q2 2026. Gross margin 89.8% against 89.0% (+0.8 pts).
BeOne Medicines, Q2 2026: revenue $1.7B (+30% year over year), operating margin 19.1%, net earnings $237M, operating cash flow $463M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 89.8% | 89.0% | +0.8 pts |
| Operating margin | 19.1% | 16.5% | +2.6 pts |
| Net margin | 13.9% | 15.0% | -1.1 pts |
| Free cash flow margin | 25.5% | 10.6% | +14.9 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.7B | $1.5B | $192M | +13% |
| Gross profit | $1.5B | $1.3B | $184M | +14% |
| Cost of revenue | $175M | $167M | $7.3M | +4% |
| Operating profit | $325M | $250M | $75.1M | +30% |
| Operating expenses | $1.2B | $1.1B | $109M | +10% |
| Pre-tax earnings | $312M | $259M | $53.2M | +21% |
| Other expense, net | $12.6M | −$9.3M | $21.9M | — |
| Research & development | $612M | $541M | $71.1M | +13% |
| SG&A | $593M | $555M | $38.1M | +7% |
| Net earnings | $237M | $227M | $9.7M | +4% |
| Income tax | $75.5M | $31.9M | $43.6M | +137% |
| Depreciation & amortization | $40.5M | $41.1M | −$629K | -2% |
| Share-based compensation | $137M | $123M | $14.1M | +11% |
| Working capital & other | $47.9M | −$191M | $238M | — |
| Operating cash flow | $463M | $201M | $261M | +130% |
| Free cash flow (OCF − capex) | $435M | $161M | $275M | +171% |
| Capital expenditures | $27.5M | $40.8M | −$13.3M | -33% |
Questions
How much did BeOne Medicines's revenue grow quarter over quarter in Q2 2026?
BeOne Medicines's revenue rose $192M (+13%) from $1.5B in Q1 2026 to $1.7B in Q2 2026. Gross margin 89.8% against 89.0% (+0.8 pts).